Lupin and Zentiva Sign Pact to Commercialise Certolizumab

10 Jul 2025 CW Team

This strategic alliance aims to accelerate the availability of high-quality, cost-effective biosimilar Certolizumab Pegol to patients worldwide.

Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories. Zentiva will oversee commercialization activities outside USA and Canada, predominantly in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada.

Both parties will invest in the development of the new biosimilar. Lupin will receive an initial payment of $10 million upon execution of the agreement and total development and regulatory milestone payments up to $50 million. The profits from the defined markets will be shared between the two companies.

Certolizumab Pegol is a recombinant, humanized antibody Fab' fragment, with specificity for human tumor necrosis factor alpha (TNFα), conjugated to an approximately 40kDa polyethylene glycol. It is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, moderate-to-severe plaque psoriasis and Crohn’s disease.

“Our global development and commercialization partnership with Zentiva, with its pan- European focus, enables Lupin to commercialize this unique biosimilar in its core markets and through Zentiva in Europe,” said Fabrice Egros, President of Corporate Development, Lupin. “This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions and ensuring accessibility and affordability of transformative therapies worldwide."

Global Pharma major Lupin (Lupin) and Zentiva Group (Zentiva), a pan-European pharmaceutical company, have entered into a license and supply agreement for commercialisation of Lupin’s biosimilar Certolizumab Pegol, across multiple markets globally.This strategic alliance aims to accelerate the availability of high-quality, cost-effective biosimilar Certolizumab Pegol to patients worldwide.Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories. Zentiva will oversee commercialization activities outside USA and Canada, predominantly in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada.Both parties will invest in the development of the new biosimilar. Lupin will receive an initial payment of $10 million upon execution of the agreement and total development and regulatory milestone payments up to $50 million. The profits from the defined markets will be shared between the two companies.Certolizumab Pegol is a recombinant, humanized antibody Fab' fragment, with specificity for human tumor necrosis factor alpha (TNFα), conjugated to an approximately 40kDa polyethylene glycol. It is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, moderate-to-severe plaque psoriasis and Crohn’s disease.“Our global development and commercialization partnership with Zentiva, with its pan- European focus, enables Lupin to commercialize this unique biosimilar in its core markets and through Zentiva in Europe,” said Fabrice Egros, President of Corporate Development, Lupin. “This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions and ensuring accessibility and affordability of transformative therapies worldwide.

Infrastructure Urban

01 Oct 2025

REC Launches Rs 50.71 Mn Mobile Medical Units in Rajasthan

In a bid to make quality healthcare accessible to remote and underserved communities, REC has extended financial support of Rs 50.71 million under its CSR initiative to the Indian Red Cross Society, Alwar, for operating five Mobile Medical Units (MMUs) over the next three years.The MMUs were flagged off on October 5, 2025, by Bhupender Yadav, Hon’ble Union Minister of Environment, Forest & Climate Change, and Sanjay Sharma, Minister of Environment, Forest & Climate Change and Science & Technology, Government of Rajasthan.The event was attended by members of the REC CSR team, M L ..

Products

07 Oct 2025

Utility-Scale Inverter

Polycab’s UT 1500V Series (350kW) three-phase string inverter features 15/12 MPPTs, supports bifacial 182mm/210mm modules, includes optional Anti-PID and PID-recovery, operates in -35°C to +60°C, and ensures high efficiency, safety, and cost-effective utility-scale PV performance.Contact: PolycabWebsite: https://polycab.com/ ..

Resources

07 Oct 2025

Shyam Metalics CMD Brij Bhushan Agarwal Elected ICC President

Brij Bhushan Agarwal, Chairman and Managing Director of Shyam Metalics, has been elected President of the Indian Chamber of Commerce (ICC), after serving as Senior Vice President. Agarwal brings decades of experience in the metals and mining sector and has guided Shyam Metalics into a leading integrated metal producer with strong steel, ferro alloys, and aluminum operations. He has also been active in social initiatives spanning education, healthcare, rural development, and skill enhancement. As ICC President, he aims to strengthen the Chamber’s role in supporting sustainable growt..